Literature DB >> 20689984

Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures.

Torbjörn Åkerfeldt1, Anders Larsson.   

Abstract

Pentraxin 3 is an acute phase marker that belongs to the same protein family as C-reactive protein (CRP). The aim of this study was to compare the acute phase reactions of pentraxin 3 and CRP in humans. High sensitivity CRP and pentraxin 3 were analyzed in blood samples from orthopedic surgery (n = 29) and coronary bypass patients (n = 21). The samples were collected prior to surgery and 4 and 30 days after surgery, respectively. Both CRP and pentraxin 3 were significantly increased at day 4. Median pentraxin 3 values increased from 4,021 to 7,459 pg/mL in the orthopedic group and from 4,637 pg/mL to 10,419 pg/mL in the coronary bypass group while CRP increased from 6.3 mg/L to 151.6 mg/L and from 5.7 mg/L to 176.3 mg/L in the same groups. Pentraxin 3 shows a much smaller increment in humans in comparison with CRP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20689984     DOI: 10.1007/s10753-010-9243-y

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  13 in total

Review 1.  Long pentraxin 3 in pulmonary infection and acute lung injury.

Authors:  Xiaolin He; Bing Han; Mingyao Liu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-02-02       Impact factor: 5.464

2.  Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.

Authors:  Giuseppe Danilo Norata; Patrizia Marchesi; Vivek Krishna Pulakazhi Venu; Fabio Pasqualini; Achille Anselmo; Federica Moalli; Irene Pizzitola; Cecilia Garlanda; Alberto Mantovani; Alberico Luigi Catapano
Journal:  Circulation       Date:  2009-08-10       Impact factor: 29.690

3.  Increased serum pentraxin 3 in patients with systemic sclerosis.

Authors:  Yohei Iwata; Ayumi Yoshizaki; Fumihide Ogawa; Kazuhiro Komura; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Kazuhiko Takehara; Shinichi Sato
Journal:  J Rheumatol       Date:  2009-02-27       Impact factor: 4.666

4.  Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells.

Authors:  Andrea Doni; Giovanna Mantovani; Chiara Porta; Jan Tuckermann; Holger M Reichardt; Anna Kleiman; Marina Sironi; Luca Rubino; Fabio Pasqualini; Manuela Nebuloni; Stefano Signorini; Giuseppe Peri; Antonio Sica; Paolo Beck-Peccoz; Barbara Bottazzi; Alberto Mantovani
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

5.  Elevation of plasma levels of the long pentraxin 3 precedes preeclampsia in pregnant patients with type 1 diabetes.

Authors:  Maria Teresa Castiglioni; Marina Scavini; Rubina Cavallin; Federica Pasi; Susanna Rosa; Maria Grazia Sabbadini; Patrizia Rovere-Querini
Journal:  Autoimmunity       Date:  2009-05       Impact factor: 2.815

Review 6.  The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity.

Authors:  Barbara Bottazzi; Cecilia Garlanda; Alessia Cotena; Federica Moalli; Sebastien Jaillon; Livija Deban; Alberto Mantovani
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

Review 7.  Pattern recognition by pentraxins.

Authors:  Alok Agrawal; Prem Prakash Singh; Barbara Bottazzi; Cecilia Garlanda; Alberto Mantovani
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

8.  Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus.

Authors:  J Kim; J K Koh; E Y Lee; J A Park; H A Kim; E B Lee; C Garlanda; A Cotena; Y W Song
Journal:  Clin Exp Rheumatol       Date:  2009 Sep-Oct       Impact factor: 4.473

9.  Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study.

Authors:  Nancy Swords Jenny; Alice M Arnold; Lewis H Kuller; Russell P Tracy; Bruce M Psaty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-22       Impact factor: 8.311

10.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

View more
  5 in total

1.  High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients.

Authors:  Matti Vänskä; Irma Koivula; Sari Hämäläinen; Kari Pulkki; Tapio Nousiainen; Esa Jantunen; Auni Juutilainen
Journal:  Haematologica       Date:  2011-09       Impact factor: 9.941

2.  Preoperative methylprednisolone increases plasma Pentraxin 3 early after total knee arthroplasty: a randomized, double-blind, placebo-controlled trial.

Authors:  V Lindberg-Larsen; H Kehlet; K Pilely; J Bagger; M L Rovsing; P Garred
Journal:  Clin Exp Immunol       Date:  2017-11-09       Impact factor: 4.330

3.  Implications of pentraxin 3 levels in patients with acute aortic dissection.

Authors:  Kenshiro Arao; Takayuki Fujiwara; Yousuke Taniguchi; Hiroyuki Jinnouchi; Harue Sasai; Mitsunari Matsumoto; Hiroshi Funayama; Junya Ako; Shin-ichi Momomura
Journal:  Heart Vessels       Date:  2014-01-29       Impact factor: 2.037

4.  Elective orthopedic and cardiopulmonary bypass surgery causes a reduction in serum endostatin levels.

Authors:  Torbjörn Åkerfeldt; Lena Gunningberg; Christine Leo Swenne; Göran Ronquist; Anders Larsson
Journal:  Eur J Med Res       Date:  2014-11-08       Impact factor: 2.175

5.  Elevated plasma pentraxin 3 and its association with retinal vein occlusion.

Authors:  Kyung Soo Park; Ji Wan Kim; Jae Hwan An; Je Moon Woo
Journal:  Korean J Ophthalmol       Date:  2014-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.